LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 2 | B15 | 72 | hr | 2543 | 2036 | 5761 | 0.3534 | -0.1719 |
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 3 | B15 | 72 | hr | 2543 | 2094 | 5760 | 0.3635 | -0.1520 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 1 | B14 | 72 | hr | 2543 | 1948 | 5734 | 0.3397 | -0.2034 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 2 | B14 | 72 | hr | 2543 | 1963 | 5761 | 0.3407 | -0.1972 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 3 | B14 | 72 | hr | 2543 | 2008 | 5760 | 0.3486 | -0.1816 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 1 | B13 | 72 | hr | 2543 | 2103 | 5734 | 0.3667 | -0.1497 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 2 | B13 | 72 | hr | 2543 | 2184 | 5761 | 0.3791 | -0.1212 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 3 | B13 | 72 | hr | 2543 | 2217 | 5760 | 0.3848 | -0.1099 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 1 | N18 | 72 | hr | 2543 | 5120 | 5258 | 0.9736 | 0.9496 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 2 | N18 | 72 | hr | 2543 | 5691 | 5438 | 1.0465 | 1.0847 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 3 | N18 | 72 | hr | 2543 | 6051 | 5557 | 1.0888 | 1.1568 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 1 | N17 | 72 | hr | 2543 | 5140 | 5258 | 0.9774 | 0.9568 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 2 | N17 | 72 | hr | 2543 | 5680 | 5438 | 1.0445 | 1.0810 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 3 | N17 | 72 | hr | 2543 | 5694 | 5557 | 1.0246 | 1.0436 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 1 | N16 | 72 | hr | 2543 | 4749 | 5258 | 0.9031 | 0.8145 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 2 | N16 | 72 | hr | 2543 | 5567 | 5438 | 1.0237 | 1.0432 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 3 | N16 | 72 | hr | 2543 | 5792 | 5557 | 1.0422 | 1.0747 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 1 | N15 | 72 | hr | 2543 | 5187 | 5258 | 0.9863 | 0.9739 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 2 | N15 | 72 | hr | 2543 | 5585 | 5438 | 1.0270 | 1.0492 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 3 | N15 | 72 | hr | 2543 | 5797 | 5557 | 1.0431 | 1.0763 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 1 | N14 | 72 | hr | 2543 | 5025 | 5258 | 0.9555 | 0.9150 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 2 | N14 | 72 | hr | 2543 | 5932 | 5438 | 1.0908 | 1.1650 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 3 | N14 | 72 | hr | 2543 | 5901 | 5557 | 1.0618 | 1.1093 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 1 | N13 | 72 | hr | 2543 | 4719 | 5258 | 0.8973 | 0.8036 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 2 | N13 | 72 | hr | 2543 | 5400 | 5438 | 0.9930 | 0.9872 |